Shattuck Labs/STTK

$10.01

-0.1%
-
1D1W1MYTD1YMAX

About Shattuck Labs

Shattuck Labs, Inc. is a clinical-stage biotechnology company. The Company is engaged in the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Its lead product candidate, SL-172154, is designed to simultaneously inhibit the CD47/SIRPa macrophage checkpoint interaction and activate the CD40 costimulatory receptor to induce an antitumor immune response. It is conducting a Phase IA/B clinical trial in patients with acute myeloid leukemia (AML) and HR-MDS. It has completed the Phase IA dose-escalation portion of this clinical trial and are enrolling patients in the Phase IB expansion cohorts evaluating SL-172154 in combination with azacitidine in frontline HR-MDS or frontline TP53 mutant (TP53m) AML. It has developed the ARC platform to address the need for a single therapeutic that consolidates multiple immune functions.

Ticker

STTK

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Taylor Schreiber

Employees

75

Headquarters

Austin, United States

Shattuck Labs Metrics

BasicAdvanced
$431.55M
Market cap
-
P/E ratio
-$2.05
EPS
2.10
Beta
-
Dividend rate
$431.55M
2.10459
$11.11
$1.33
324.47K
12.505
-47.85%
-54.41%
-53.15%
260.438
2.969
2.982
154.14%
14.76%
-44.95%

What the Analysts think about Shattuck Labs

Analyst Ratings

Majority rating from 6 analysts.
Buy

Price Targets

Average projection from 4 analysts.
57.34% upside
High $28.00
Low $11.00
$10.01
Current price
$15.75
Average price target

Shattuck Labs Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-2,514.28% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$700K
16.67%
Net income
$-17.6M
-36%
Profit margin
-2,514.28%
-45.14%

Shattuck Labs Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 27.84%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.49
-$0.50
-$0.65
-$0.41
-
Expected
-$0.63
-$0.52
-$0.52
-$0.57
-$0.45
Surprise
-22.15%
-3.33%
25.2%
-27.84%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Shattuck Labs stock?

Shattuck Labs (STTK) has a market cap of $431.55M as of April 18, 2024.

What is the P/E ratio for Shattuck Labs stock?

The price to earnings (P/E) ratio for Shattuck Labs (STTK) stock is 0 as of April 18, 2024.

Does Shattuck Labs stock pay dividends?

No, Shattuck Labs (STTK) stock does not pay dividends to its shareholders as of April 18, 2024.

When is the next Shattuck Labs dividend payment date?

Shattuck Labs (STTK) stock does not pay dividends to its shareholders.

What is the beta indicator for Shattuck Labs?

Shattuck Labs (STTK) has a beta rating of 2.1. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Shattuck Labs stock price target?

The target price for Shattuck Labs (STTK) stock is $15.75, which is 57.34% above the current price of $10.01. This is an average based on projections from 4 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Shattuck Labs stock

Buy or sell Shattuck Labs stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing